Bank­ing on in­te­grase in­hibitors as HIV cor­ner­stone, Vi­iV bags 3rd-gen­er­a­tion com­pound from Sh­iono­gi

As a 12% share­hold­er of Vi­iV Health­care, Japan’s Sh­iono­gi has com­mand­ed a much low­er pro­file than its fel­low own­ers, Glax­o­SmithK­line and Pfiz­er. But be­hind the scenes, it’s played an out­sized role in the de­vel­op­ment of Vi­iV’s HIV drugs, com­ing up with the two top pro­grams — the in­te­grase in­hibitors do­lute­gravir and cabote­gravir — cur­rent­ly in Vi­iV’s port­fo­lio.

And it’s time for round three.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER